Orencia Fails to Reduce Disease Activity in Patients with Early Active Primary Sjögren’s Syndrome, Trial Shows
Orencia (abatacept), an immunotherapy used in rheumatic diseases, failed to reduce disease activity in patients with early active primary Sjögren’s syndrome after 24 weeks of treatment, results from the ASAPIII Phase 3 trial show. However, more patients reported an easing of disease symptoms while taking Orencia, compared…